Subscribe
Tada Images / Shutterstock.com
26 June 2025NewsEuropeMarisa Woutersen

Broad Institute wins appeal to restore CRISPR patent in Europe

Biotech institute successfully challenges EPO decision revoking key CRISPR patent over priority rights | Appeal follows major changes to European law | Case returns to lower court for novelty and inventive step evaluation.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
‘It’s business as usual’: ERS Genomics enjoys new EPO patent after CRISPR gambit pays off
27 February 2025   The licensing company’s CEO and GC accept that ‘tactical retreats and tactical gains’ are baked into the high-profile portfolio’s future, finds Marisa Woutersen.
Europe
Broad Institute presses for CRISPR settlement after EPO revocation
23 January 2020   A competitor of the Broad Institute has said that a European Patent Office ruling last week has weakened the CRISPR/Cas9 patent owner’s negotiating hand in any future settlement between the parties.
Europe
Breaking: EPO board to refer key issues in Broad appeal to higher panel
15 January 2020   The European Patent Office intends to refer questions in the Broad Institute’s ongoing CRISPR patent case to the enlarged board of appeal, meaning the case is set to drag out further.


Editor's picks

A step too far? Why Stewart’s approach is dividing opinion
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025

Editor's picks

Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025

More on this story

Europe
‘It’s business as usual’: ERS Genomics enjoys new EPO patent after CRISPR gambit pays off
27 February 2025   The licensing company’s CEO and GC accept that ‘tactical retreats and tactical gains’ are baked into the high-profile portfolio’s future, finds Marisa Woutersen.
Europe
Broad Institute presses for CRISPR settlement after EPO revocation
23 January 2020   A competitor of the Broad Institute has said that a European Patent Office ruling last week has weakened the CRISPR/Cas9 patent owner’s negotiating hand in any future settlement between the parties.
Europe
Breaking: EPO board to refer key issues in Broad appeal to higher panel
15 January 2020   The European Patent Office intends to refer questions in the Broad Institute’s ongoing CRISPR patent case to the enlarged board of appeal, meaning the case is set to drag out further.

More on this story

Europe
‘It’s business as usual’: ERS Genomics enjoys new EPO patent after CRISPR gambit pays off
27 February 2025   The licensing company’s CEO and GC accept that ‘tactical retreats and tactical gains’ are baked into the high-profile portfolio’s future, finds Marisa Woutersen.
Europe
Broad Institute presses for CRISPR settlement after EPO revocation
23 January 2020   A competitor of the Broad Institute has said that a European Patent Office ruling last week has weakened the CRISPR/Cas9 patent owner’s negotiating hand in any future settlement between the parties.
Europe
Breaking: EPO board to refer key issues in Broad appeal to higher panel
15 January 2020   The European Patent Office intends to refer questions in the Broad Institute’s ongoing CRISPR patent case to the enlarged board of appeal, meaning the case is set to drag out further.

More features

BMS faces fresh lawsuit over alleged cancer drug monopoly
WATCH: Synergy in science—navigating the landscape of pharmaceutical collaborations
Boies Schiller Flexner adds three-strong litigation team
AstraZeneca forced to clarify deal terms in row with university
Novartis loses cancer drug patent following Teva challenge at EPO
A step too far? Why Stewart’s approach is dividing opinion
WATCH: Section 112—Where has the dust settled?
UPC rejects Alexion’s rehearing bid in spat with Amgen and Samsung